– Katrin Rupalla, Ph.D., appointed Chair of Ambrx’s Board of Directors – – Ambrx to conduct strategic pipeline review with focus on commercial opportunity and cash runway extension – – Dr. Tian will continue to be available to Ambrx in an advisory capacity – SAN DIEGO–(BUSINESS WIRE)–Ambrx Biopharma Inc., or […]

SAN DIEGO–(BUSINESS WIRE)–​Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the appointments of Edward Hu and Kate Hermans to its Board of Directors. “I am delighted to welcome both Edward and […]

SAN DIEGO–(BUSINESS WIRE)–Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the appointment of Janice Lu, M.D., Ph.D., as Chief Medical Officer of Ambrx. Dr. Lu is a distinguished clinical professor of […]